Contrasting Uroplasty (UPI) and Its Rivals

Uroplasty (NASDAQ: UPI) is one of 19 publicly-traded companies in the “Medical Devices & Implants” industry, but how does it contrast to its competitors? We will compare Uroplasty to related businesses based on the strength of its institutional ownership, analyst recommendations, dividends, profitability, valuation, earnings and risk.

Profitability

This table compares Uroplasty and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Uroplasty -31.58% -87.33% -60.82%
Uroplasty Competitors -97.44% -91.73% -29.33%

Analyst Recommendations

This is a summary of current recommendations and price targets for Uroplasty and its competitors, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Uroplasty 0 0 0 0 N/A
Uroplasty Competitors 109 727 1024 10 2.50

As a group, “Medical Devices & Implants” companies have a potential upside of 35.54%. Given Uroplasty’s competitors higher probable upside, analysts clearly believe Uroplasty has less favorable growth aspects than its competitors.

Earnings & Valuation

This table compares Uroplasty and its competitors top-line revenue, earnings per share and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
Uroplasty N/A N/A -1.09
Uroplasty Competitors $1.67 billion $207.58 million 61.43

Uroplasty’s competitors have higher revenue and earnings than Uroplasty. Uroplasty is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Volatility and Risk

Uroplasty has a beta of -1.26, meaning that its stock price is 226% less volatile than the S&P 500. Comparatively, Uroplasty’s competitors have a beta of 0.36, meaning that their average stock price is 64% less volatile than the S&P 500.

Institutional & Insider Ownership

57.4% of shares of all “Medical Devices & Implants” companies are held by institutional investors. 11.2% of shares of all “Medical Devices & Implants” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Uroplasty competitors beat Uroplasty on 6 of the 8 factors compared.

Uroplasty Company Profile

Cogentix Medical, Inc. (Cogentix Medical) is a medical device company. The Company is engaged in the design, development, manufacturing and marketing of products for endoscopy with its product lines featuring a visualization system and sterile disposable microbial barrier, known as EndoSheath technology, providing users with endoscope turnover. The Company’s products include Urgent PC Neuromodulation System, Macroplastique Bulking Agent, Endoscopy Systems and EndoSheath Technology. The Company is also engaged in the commercialization of the Urgent PC Neuromodulation System, a device which delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder (OAB). Its Macroplastique is an injectable soft-tissue bulking agent used to treat stress urinary incontinence (SUI) due to intrinsic sphincter deficiency (ISD). The Company offers 5000 and 7000 series of endoscopes, which are video endoscopy systems.

What are top analysts saying about Uroplasty Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Uroplasty Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit